Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 9/20 | 0.52 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.48 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.48 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.47 |
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.47 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.47 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.47 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.47 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.47 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.47 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.47 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.47 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.47 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.47 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.47 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.47 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.47 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 0.47 |
| ▸ | GABRG3 known ✓ | Q99928 | 1/20 | 0.47 |
| ▸ | GABRQ known ✓ | Q9UN88 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4653034 | 1.00 | CDC25B (0.59) | CDC25BLMNAKDM4EGAAMAPT | |
| SCHEMBL77186 | 0.98 | CDC25B (0.61) | CDC25BLMNAKDM4EGAAMAPT | |
| SCHEMBL29351778 | 0.98 | CDC25B (0.61) | CDC25BLMNAKDM4EGAAMAPT | |
| SCHEMBL4824967 | 0.98 | CDC25B (0.61) | CDC25BLMNAKDM4EGAAMAPT | |
| SCHEMBL2892151 | 0.95 | CDC25B (0.59) | CDC25BLMNAKDM4EGAAMAPT | |
| SCHEMBL8648893 | 0.95 | CDC25B (0.59) | CDC25BLMNAKDM4EGAAMAPT | |
| Water SCHEMBL2810848 | 0.95 | CDC25B (0.59) | CDC25BLMNAKDM4EGAAMAPT | |
| SCHEMBL2814914 | 0.95 | CDC25B (0.59) | CDC25BLMNAKDM4EGAAMAPT | |
| SCHEMBL2808434 | 0.95 | CDC25B (0.59) | CDC25BLMNAKDM4EGAAMAPT | |
| SCHEMBL8983903 | 0.89 | CDC25B (0.53) | CDC25BLMNAKDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111812253-A | Method for detecting potential genotoxic impurities in compound containing benzimidazole structure | 天津汉一医药科技有限公司 | 2020-10-23 | — | — | CN | claimed |
| CN-115626990-A | Synthesis and polymerization method of AB type polybenzoxazole monomer containing benzimidazole structure | 浙江理工大学 | 2023-01-20 | — | — | CN | disclosed |
| CN-111812253-A | Method for detecting potential genotoxic impurities in compound containing benzimidazole structure | 天津汉一医药科技有限公司 | 2020-10-23 | — | — | CN | disclosed |
| US-10323338-B2 | Process for making composites comprising rigid-rod polymers and graphene nanoparticles | TJC Polymer Inc. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20180105957-A1 | PROCESS FOR MAKING COMPOSITES COMPRISING RIGID-ROD POLYMERS AND GRAPHENE NANOPARTICLES | DANG THUY D (US) | 2018-04-19 | — | — | US | disclosed |
| US-9850596-B2 | Composites comprising rigid-rod polymers and graphene nanoparticles and process for making the same | TJC Polymer Inc. (US) | 2017-12-26 | — | — | US | disclosed |
| EP-2291703-B1 | COLOR LIQUID CRYSTAL DISPLAY AND COMPENSATION PANEL | CRYSOPTIX KK (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-20150218730-A1 | COMPOSITES COMPRISING RIGID-ROD POLYMERS AND GRAPHENE NANOPARTICLES AND PROCESS FOR MAKING THE SAME | DANG THUY D (US) | 2015-08-06 | — | — | US | disclosed |
| EP-2638126-B1 | NEGATIVE DISPERSION RETARDATION PLATE AND ACHROMATIC CIRCULAR POLARIZER | CRYSOPTIX KK (JP) | 2015-02-18 | — | — | EP | disclosed |
| US-8895118-B2 | Negative dispersion retardation plate and achromatic circular polarizer | CRYSOPTIX K.K. (JP) | 2014-11-25 | — | — | US | disclosed |
| WO-2007042788-A2 | ACENAPHTHOQUINOXALINE SULFONAMIDE DERIVATIVES, OPTICAL CRYSTAL FILM AND METHOD OF PRODUCTION THEREOF | CRYSOPTIX LIMITED (CY) | 2007-04-19 | — | — | WO | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
| US-4578432-A | POLYOXAZOLES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 1986-03-25 | — | — | US | disclosed |
| US-4578434-A | POLYBENZIMIDAZOLES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 1986-03-25 | — | — | US | disclosed |
| US-4578435-A | POLYBENZIMIDIZOLES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 1986-03-25 | — | — | US | disclosed |
| US-4544713-A | RIGID AND FLEXIBLE SEGMENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) | 1985-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | GAA 264/4885CA2 740/4885PTGS2 1528/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | GAA 352/4885CA2 649/4885PTGS2 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.